Lipocine Inc. [LPCN] Stock trading around $2.12 per share: What’s Next?

Lipocine Inc. [NASDAQ: LPCN] gained 3.92% or 0.08 points to close at $2.12 with a heavy trading volume of 7583534 shares. The company report on January 29, 2021 that Lipocine Closes Underwritten Public Offering Of Common Stock.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced the closing of an underwritten public offering of 16,428,571 shares of its common stock, offered at a price of $1.75 to the public, which included the exercise in full by the underwriters of their option to purchase 2,142,857 additional shares of common stock at the public offering price. Gross proceeds to Lipocine were approximately $28.7 million before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Raymond James & Associates, Inc. acted as sole book-running manager and Ladenburg Thalmann & Co. Inc. acted as co-manager for the public offering.

It opened the trading session at $2.105, the shares rose to $2.28 and dropped to $2.00, the range by which the price of stock traded the whole day. The daily chart for LPCN points out that the company has recorded 0.00% loss over the past six months. However, it is still -606.67% lower than its most recent low trading price.

If we look at the average trading volume of 4.50M shares, LPCN reached to a volume of 7583534 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Lipocine Inc. [LPCN]:

Ladenburg Thalmann have made an estimate for Lipocine Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 10, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $10 to $3. The new note on the price target was released on January 12, 2018, representing the official price target for Lipocine Inc. stock. Previously, the target price had yet another drop from $11 to $2, while Canaccord Genuity kept a Hold rating on LPCN stock.

The Average True Range (ATR) for Lipocine Inc. is set at 0.19 The Price to Book ratio for the last quarter was 9.64, with the Price to Cash per share for the same quarter was set at 0.23.

Trading performance analysis for LPCN stock

Lipocine Inc. [LPCN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 19.77. With this latest performance, LPCN shares gained by 26.95% in over the last four-week period, additionally sinking by 0.00% over the last 6 months – not to mention a rise of 366.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LPCN stock in for the last two-week period is set at 65.65, with the RSI for the last a single of trading hit 69.99, and the three-weeks RSI is set at 63.27 for Lipocine Inc. [LPCN]. The present Moving Average for the last 50 days of trading for this stock 1.63, while it was recorded at 1.96 for the last single week of trading, and 1.39 for the last 200 days.

Lipocine Inc. [LPCN]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Lipocine Inc. [LPCN] shares currently have an operating margin of -7818.83. Lipocine Inc.’s Net Margin is presently recorded at -7883.72.

Return on Total Capital for LPCN is now -77.88, given the latest momentum, and Return on Invested Capital for the company is -98.31. Return on Equity for this stock declined to -165.47, with Return on Assets sitting at -64.22. When it comes to the capital structure of this company, Lipocine Inc. [LPCN] has a Total Debt to Total Equity ratio set at 113.68. Additionally, LPCN Total Debt to Total Capital is recorded at 53.20, with Total Debt to Total Assets ending up at 36.36. Long-Term Debt to Equity for the company is recorded at 60.66, with the Long-Term Debt to Total Capital now at 28.39.

Reflecting on the efficiency of the workforce at the company, Lipocine Inc. [LPCN] managed to generate an average of -$1,083,945 per employee. Receivables Turnover for the company is 6.00 with a Total Asset Turnover recorded at a value of 0.01.Lipocine Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.30 and a Current Ratio set at 4.30.

Lipocine Inc. [LPCN]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Lipocine Inc. posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.15/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LPCN.

An analysis of insider ownership at Lipocine Inc. [LPCN]

There are presently around $16 million, or 8.80% of LPCN stock, in the hands of institutional investors. The top three institutional holders of LPCN stocks are: VANGUARD GROUP INC with ownership of 2,957,883, which is approximately 167.85% of the company’s market cap and around 2.60% of the total institutional ownership; BLACKROCK INC., holding 1,618,913 shares of the stock with an approximate value of $3.43 million in LPCN stocks shares; and AMERIPRISE FINANCIAL INC, currently with $1.67 million in LPCN stock with ownership of nearly -0.317% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Lipocine Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 19 institutional holders increased their position in Lipocine Inc. [NASDAQ:LPCN] by around 3,283,191 shares. Additionally, 12 investors decreased positions by around 519,248 shares, while 8 investors held positions by with 3,855,723 shares. The mentioned changes placed institutional holdings at 7,658,162 shares, according to the latest SEC report filing. LPCN stock had 7 new institutional investments in for a total of 469,497 shares, while 9 institutional investors sold positions of 482,549 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam